Harish Seethapathy
800 posts
user avatar
Harish Seethapathy
@BetterCallSeeth
Nephrologist @MGHkidneys | #Onconephrology | @GlomCon #Fellowship | #ASON
Boston, MA
Joined January 2019
474
Following
2,466
Followers
  • Pinned
    user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Oct 25, 2023
    🚀Na over-correction (Na📈) as THE (only) cause of ODS/CPM: An absurd over-simplification. Since 1980s, Na📈 has been portrayed as the main cause of CPM (so far as now the terms ODS and CPM are used synonymously). However, finding the truth (if it exists) is more complicated.
    107K
  • user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Sep 26, 2023
    Our publication on HypoNa correction rates in @NEJMEvidence is out! Lots of discussion to come, but want to convey a big thanks to our co-authors. Very grateful for @sagarnigs - extremely fortunate to have his incredible mentorship & support.
    user avatar
    Sagar Nigwekar
    @sagarnigs
    Sep 26, 2023
    New publication from our group. Severe Hyponatremia Correction, Mortality, and Central Pontine Myelinolysis | NEJM Evidence evidence.nejm.org/doi/full/10.10… @ASNKidney
    15K
  • user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Nov 4, 2021
    My 1st #KidneyWk talk just dropped! And its on #Diwali 🧨🧨 To celebrate, here is a snippet as a thread.. 'CAR-T and the Kidneys: Why does it matter?'
  • user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Jun 3, 2023
    Truly amazing debates with >170 participants @GlomCon. Thanks to everyone who joined/presented and to @NephRodby & @TWhittier_RUSH Cyclo vs Ritux for PLA2R+ Membranous Clinical utility of Lupus ISN/RPS classification in 2023 PLEX - Yay or Nay in ANCA without pulm hemorrhage
    Image
    Image
    Image
    13K
  • user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Dec 11, 2021
    As is tradition, zoom group photo at our Joint Case Conference @GlomCon #Fellowship #Nephrin #Podocin Insightful, deep, thoughtful, nerdy..in short terrific discussions today! Wow to such amazing colleagues.
    Image
    Image
    Image
    Image
  • user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Dec 4, 2019
    Board Certified in Nephrology 😅 Relieved. Gosh that was one tough exam with so many ambiguous questions. @MGHKidneys @BWHKidney
    Image
  • user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Apr 14, 2022
    Kicking off the onconephrology fun at the @GlomCon fellowship 4 faculty panelists 4 fellow presenters Guess what is common.. All 8 are phenomenal @womeninnephro
    Image
  • user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Sep 14, 2023
    And so it begins.. Another year of learning and getting to know some awesome people!
    Image
    6.1K
  • user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Oct 25, 2023
    Replying to @BetterCallSeeth
    Summary: ✅CPM has many risk factors other than Na 📈 ✅CPM predominantly occurs in non-hyponatremic settings ✅Na 📈 is the straw that breaks the camel’s back & recent evidence does not back up claims that 6 or 8/24h is safe. ✅High risk pts (Alcoholism/malnutrition etc.) →
    6.1K
  • user avatar
    Harish Seethapathy
    @BetterCallSeeth
    Jan 13, 2020
    Really pleased that our paper on ICIs and AKI was so well received by many. Also my first OI manuscript with @MegSise an amazing mentor, who is so much fun to work with. Thanks to @CJASN for the recognition. @MGHKidneys
    user avatar
    ASN Publications
    @asnpublications
    Jan 13, 2020
    Editor's Pick of @CJASN 2019: The Incidence, Causes, and Risk Factors of #AcuteKidneyInjury in Patients Receiving Immune Checkpoint Inhibitors bit.ly/CJN00990119 @BetterCallSeeth @megsise @mghnephrology
    Image

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms of Service|Privacy Policy|Cookie Policy|Accessibility|Ads info|© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
Advertisement
Advertisement